Shield Therapeutics achieving significant milestones
Last updated: 20:40 03 Feb 2020 AEDT, First published: 20:37 03 Feb 2020 AEDT
Shield Therapeutics (STX) detailed a series of achievements in its FY19 business update. The highlights included a 67% increase in sales volumes in European markets and, notably, FDA approval of Feraccru (Accrufer) with the broadest possible label to treat iron deficiency with or without anaemia. It also delivered a post-period announcement of an attractive licensing deal with ASK Pharm in China. The very positive body of clinical data, and the product profile, position Accrufer to challenge market incumbents in US, an addressable market worth up to $2bn, whilst the deal with ASK Pharm improves the company’s financial, strategic and commercial prospects and opens the door to China, the world’s second largest pharma market.
|
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities,...
In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC...
FOR OUR FULL DISCLAIMER CLICK HEREThis document is published by Proactive Research and its contents have not been approved as a financial promotion by Proactive Investors Limited or any other FCA authorised person. This communication is made on the basis of the 'journalist exemption' provide for in Article 20 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and having regard to the FCA rules, and in particular PERG 8.12.
Where the note contains a ‘buy, sell, hold’ recommend, Proactive Investors Limited is authorised to provide investment advice as defined by Article 53 of the RAO
FOR OUR FULL DISCLAIMER CLICK HERE